Abstract
Studies are being carried out in developing formulations for current and proprietary active pharmaceutical ingredients (APIs) to be delivered by a metered dose inhaler in HFC-152a or HFO-1234ze. Studies are being carried out on reformulating existing API formulations, in particular existing marketed inhaled formulations in 134a or 227ea, with HFC-152a or HFO-1234ze. The API formulations may be in any suitable form, such as in solution or suspension.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Anonymous, "Reformulating pharmaceuticals in low GWP propellants", Technical Disclosure Commons, (July 14, 2024)
https://www.tdcommons.org/dpubs_series/7180